CHEMO PHARMA LABORATORIES LIMITED

- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI 400 001
 - TEL: 91-22-22078381, 22078382 FAX: 91-22-22074294
 - CIN No.: L999999MH1942PLC003556 PAN No.: AAACC2056K

www.thechemopharmalaboratoriesltd.com

EMAIL: chemopharmalab@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2014

(Rs in '000)

			(Rs in '000)				
	Particulars	Quarter Ended			Nine Mon	Year Ended	
Sr. No.		31st December, 2014	30th September, 2014	31st December, 2013 Unaudited	31st December, 2014 Unaudited	31st December, 2013	31st March, 2014 Audited
		Unaudited	Unaudited			Unaudited	
1	Income from Operations						
	(a) Net Sales/ Income from Operations (Net of excise	-					
	(b) Other Operating Income	325	1,134	227	2,563	2,014	4,388
	Total Income from operations (net)	325					
2	Expenses						
	(a) Cost of materials consumed	-		_	-	_	
1	(b) Purchases of Stock-in-trade	-		_			10 Days - 10 - 2
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade		-	-		-	
	(d) Employee benefits expenses	96	48	41	192	122	162
	(e) Depreciation and amortisation expense	16	9	11	27		46
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown seperately)	(103)		26	208		
	i) Professional Charges	45	63	49	107	346	84
	ii) Share Registry Expenses	20	26	-	64		6
	iii) Annual Listing Fees	125	-		125	-	-
	Total Expenses	199				685	1,37
	Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)	127	719	100	1,840	1,329	3,01
4	Other Income Profit / Loss from ordinary activities before	107	- 710	-		•	
5	Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4) Finance Costs	127		100		1,329	3,010
		107	710	- 100	1 040	- 1000	
8	Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6) Exceptional Items	127	719	100	1,840	1,329	3,01
	Net Profit/(Loss) from ordinary activities before tax	127	710	100	1 040	1 000	2.01
	(7+8)	127	719	100	1,840	1,329	
		127	719	100	1 940	1 200	60
1.00	(9+10)	14.	113	100	1,840	1,329	2,41
		-	-	-	-	- I+	
		127	719	100	1,840	1,329	2,41
14	Share of Profit/ (Loss) of associate*	-	-	-	-	-	572
		-	-	-	-	-	
16	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates 13+14+15)*	127	719	100	1,840	1,329	2,41
17	Paid-up equity share Capital (face value of Rs. 10/- each)	15,000	15,000	15,000	15,000	15,000	15,00
18	Reserves excluding revaluation reserve as per balance sheet of previous accounting year	35,210					
	i) Earning per share (before extraordinary items) of Rs. 10/- each) (not annualised):						
	(a) Basic	0.08	0.48	0.07	1.23	0.89	1.6
_	(b) Diluted						
	ii) Earning per share (after extraordinary items) of Rs. 10/- each) (not annualised):						
	(a) Basic	0.08	0.48	0.07	1.23	0.89	1.6
	(b) Diluted						



CHEMO PHARMA LABORATORIES LIMITED

- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI 400 001
 - TEL: 91-22-22078381, 22078382 FAX: 91-22-22074294
 - CIN No.: L99999MH1942PLC003556 PAN No.: AAACC2056K

www.thechemopharmalaboratoriesltd.com EMAIL: chemopharmalab@gmail.com

A	PARTICULARS OF SHAREHOLDING			· ·			
1	Public Shareholding						
	- Number of shares	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719
	- Percentage of shareholding	72.11	72.11	72.11	72.11	72.11	72.11
19	Promoters and Promoter Group shareholding**						
	a) Pledged/Encumbered						
	- Number of shares	NL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of company)	NIL	NIL .	NIL -	NIL	NIL -	NIL
	b) Non-Encumbered						
	- Number of shares	418,281	418,281	418,281	418,281	418,281	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of company)	27.89	27.89	27.89	27.89	27.89	27.89

Note:

 The above unaudited financial results have been taken on record by Audit Committee in their meeting on 20.01.2015 and also approved by the Board in their meeting held on 20.01.2015

2. Separate segment reporting is not applicable to the company.

Place: Mumbai

Date: 20th January, 2015

SOMBAY ON TO STORY

By Order of the Board For Chemo - Pharma Laboratories Limited

Director